Atlas Trials

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Clinical trial NCT07655622 · RECRUITING

Trial details

NCT number
NCT07655622
Sponsor
Second Affiliated Hospital of Nanchang University
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-Small-Cell Lung Cancer
Start date
2026-07-03
Primary completion
2027-12-03
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.